Our understanding of depression and its treatment has advanced with the advent of
ketamine as a rapid-acting antidepressant and the development and refinement of tools …

Depression is a common, devastating illness. Current pharmacotherapies help many
patients, but high rates of a partial response or no response, and the delayed onset of the …

Although the efficacy of racemate ketamine, a rapid onset and sustained antidepressant, for
patients with treatment-resistant depression was a serendipitous finding, clinical use of …

Impaired function in the medial prefrontal cortex (mPFC) contributes to depression, and the
therapeutic response produced by novel rapid-acting antidepressants such as ketamine are …

Major depressive disorder (MDD) is a common and debilitating psychiatric disorder.
Traditional antidepressants are of limited efficacy and take weeks to months to yield full …

Despite decades of research on the neurobiology of major depressive disorder (MDD), the
mechanisms underlying its expression remain unknown. The medial prefrontal cortex …

GLYX-13 is a putative NMDA receptor modulator with glycine-site partial agonist properties
that produces rapid antidepressant effects, but without the psychotomimetic side effects of …

Currently available antidepressants have a delayed onset and limited efficacy, highlighting
the need for new, rapid and more efficacious agents. Ketamine, an NMDA receptor …

Conventional antidepressants that target monoaminergic receptors require several weeks to
be efficacious. This lag represents a significant problem in the currently available treatments …

Pharmacological treatment of major depressive disorder (MDD) still relies on the use of
serotonergic drugs, despite their limited efficacy. A few mechanistically new drugs have …